



## INDOCO REMEDIES LIMITED

Regd. Office : Indoco House, 166, CST Road, Kalina, Santacruz (E), Mumbai 400 098.

Tel: +91-22-26541851/55 Fax: +91-22-26520787 Email: [compliance.officer@indoco.com](mailto:compliance.officer@indoco.com)

Web: [www.indoco.com](http://www.indoco.com) CIN: L85190MH1947PLC005913

### STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2018

(₹ In Lakhs)					
Sr. No	Particulars	Quarter ended 30.06.2018 (Unaudited)	Quarter ended 31.03.2018 (Audited)	Quarter ended 30.06.2017 (Unaudited)	Year ended 31.03.2018 (Audited)
<b>1</b>	<b>Income from Operations</b>				
	(a) Revenue from Operations	21,249	25,886	20,422	1,01,731
	(b) Other Operating Income	504	1,077	479	2,427
	<b>Total Income from Operations (Net) (a+b)</b>	<b>21,753</b>	<b>26,963</b>	<b>20,901</b>	<b>1,04,158</b>
<b>2</b>	<b>Other Income</b>	31	104	86	479
<b>3</b>	<b>Total Income (1+2)</b>	<b>21,784</b>	<b>27,067</b>	<b>20,987</b>	<b>1,04,637</b>
<b>4</b>	<b>Expenses</b>				
	(a) Cost of materials consumed	4,838	7,521	6,057	28,149
	(b) Purchases of stock-in-trade	1,710	1,397	1,785	6,460
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	581	(164)	(731)	330
	(d) Employee Benefits Expense	5,610	5,077	5,630	22,034
	(e) Research & Development Expense	1,321	1,378	1,357	5,349
	(f) Other Expenses	6,536	6,812	6,674	28,350
	(g) Finance Costs	718	833	609	2,351
	(h) Depreciation and Amortisation Expense	1,672	1,633	1,687	6,771
	<b>Total Expenses</b>	<b>22,986</b>	<b>24,487</b>	<b>23,068</b>	<b>99,794</b>
<b>5</b>	<b>Profit/(Loss) before Tax (3-4)</b>	<b>(1,202)</b>	<b>2,580</b>	<b>(2,081)</b>	<b>4,843</b>
<b>6</b>	<b>Tax Expenses</b>				
	- Current	-	643	-	1,107
	- Deferred	-	(321)	92	(1,006)
	- MAT Credit Adjustments	-	208	-	622
	<b>Total Tax Expenses</b>	<b>-</b>	<b>530</b>	<b>92</b>	<b>723</b>
<b>7</b>	<b>Profit/(Loss) for the period (5-6)</b>	<b>(1,202)</b>	<b>2,050</b>	<b>(2,173)</b>	<b>4,120</b>
<b>8</b>	<b>Other Comprehensive Income</b>				
<b>a</b>	<b>i) Items that will not be reclassified to profit and loss</b>	(3)	49	(5)	35
	ii) Income tax on relating to this item	1	(17)	2	(12)
<b>b</b>	<b>i) Items that may be reclassified to profit or loss</b>	-	-	-	-
	<b>Total Other Comprehensive Income</b>	<b>(2)</b>	<b>32</b>	<b>(3)</b>	<b>23</b>
<b>9</b>	<b>Total Comprehensive income for the year (7+8)</b>	<b>(1,204)</b>	<b>2,082</b>	<b>(2,176)</b>	<b>4,143</b>
<b>10</b>	Paid up Equity Share Capital (Face value ₹ 2/- each)	1,843	1,843	1,843	1,843
<b>11</b>	Other Equity				65,713
<b>12</b>	<b>Earnings per share (of ₹ 2/- each)</b>				
	(a) Basic- in ₹	(1.30)	2.22	(2.36)	4.47
	(b) Diluted- in ₹	(1.30)	2.22	(2.36)	4.47

**Notes :**

- Above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 13th August, 2018.
- The company has only one primary reportable segment of activity, namely, Pharmaceuticals.

Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows:

(₹ In Lakhs)

Net Sales and Income from Operations	Quarter ended 30.06.2018 (Unaudited)	Quarter ended 31.03.2018 (Audited)	Quarter ended 30.06.2017 (Unaudited)	Year ended 31.03.2018 (Audited)
<b>India</b>	16,359	16,217	11,022	63,335
<b>Outside India</b>	4,890	9,669	9,400	38,396
<b>Total</b>	<b>21,249</b>	<b>25,886</b>	<b>20,422</b>	<b>1,01,731</b>

- In view of losses incurred during the quarter, Management has considered it prudent not to take credit for Deferred Tax.
- The statutory auditors of the company have carried out limited review of the financial results for the quarter ended 30th June, 2018.
- The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable.

**By Order of the Board  
For Indoco Remedies Ltd**

Place : Mumbai  
Date : 13th August, 2018

**Suresh G. Kare  
Chairman**